186 related articles for article (PubMed ID: 35634280)
1. Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis.
Germanó MJ; Mackern-Oberti JP; Vitório JG; Duarte MC; Pimenta DC; Sanchez MV; Bruna FA; Lozano ES; Fernandes AP; Cargnelutti DE
Front Immunol; 2022; 13():825007. PubMed ID: 35634280
[TBL] [Abstract][Full Text] [Related]
2. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
[TBL] [Abstract][Full Text] [Related]
3. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Leishmanization Using
Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
Front Immunol; 2020; 11():1725. PubMed ID: 33193290
[No Abstract] [Full Text] [Related]
6. A recombinant fusion protein displaying murine and human MHC class I- and II-specific epitopes protects against Leishmania amazonensis infection.
Martins VT; Lage DP; Duarte MC; Carvalho AM; Costa LE; Mendes TA; Vale DL; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
Cell Immunol; 2017 Mar; 313():32-42. PubMed ID: 28049560
[TBL] [Abstract][Full Text] [Related]
7. Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.
Ramirez L; Corvo L; Duarte MC; Chávez-Fumagalli MA; Valadares DG; Santos DM; de Oliveira CI; Escutia MR; Alonso C; Bonay P; Tavares CA; Coelho EA; Soto M
Parasit Vectors; 2014 Jan; 7():3. PubMed ID: 24382098
[TBL] [Abstract][Full Text] [Related]
8. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis.
Germanó MJ; Lozano ES; Sanchez MV; Bruna FA; García-Bustos MF; Sosa Lochedino AL; Salomón MC; Fernandes AP; Mackern-Oberti JP; Cargnelutti DE
Mem Inst Oswaldo Cruz; 2020; 115():e200067. PubMed ID: 32667458
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
12. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of vaccinal effectiveness of preparations containing membrane antigens of Leishmania (L.) amazonensis in experimental cutaneous leishmaniasis model.
Ribeiro JG; Ferreira AS; Macedo SRA; Rossi NRDLP; da Silva MCP; Guerra RNM; de Barros NB; Nicolete R
Int Immunopharmacol; 2017 Jun; 47():227-230. PubMed ID: 28433944
[TBL] [Abstract][Full Text] [Related]
14. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
[TBL] [Abstract][Full Text] [Related]
16. Comparing Montanide ISA 720 and 50-V2 adjuvants formulated with LmSTI1 protein of Leishmania major indicated the potential cytokine patterns for induction of protective immune responses in BALB/c mice.
Shokri M; Roohvand F; Alimohammadian MH; Ebrahimirad M; Ajdary S
Mol Immunol; 2016 Aug; 76():108-15. PubMed ID: 27428863
[TBL] [Abstract][Full Text] [Related]
17. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
18. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
[TBL] [Abstract][Full Text] [Related]
19. Intranasal vaccination with extracellular serine proteases of Leishmania amazonensis confers protective immunity to BALB/c mice against infection.
de Matos Guedes HL; da Silva Costa BL; Chaves SP; de Oliveira Gomes DC; Nosanchuk JD; De Simone SG; Rossi-Bergmann B
Parasit Vectors; 2014 Sep; 7():448. PubMed ID: 25239157
[TBL] [Abstract][Full Text] [Related]
20. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
